http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2167093-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caec7099b724bb45d2518787825aab94 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate | 2008-06-03^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be382343be0ae18d70bd6ab279bb50ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b181e2d482315f412915c68977de978c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a776d0a20d7bb205bf4cb5d18a45b53f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d76782f3e965c5cf9512accbff0cfccb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049d140c7af79cd710b8dc06da169a0c |
| publicationDate | 2010-03-31^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2167093-A1 |
| titleOfInvention | Pharmaceutical compositions for the treatment of chronic heart failure comprising pyrazolopyrimidinone derivative compound |
| abstract | Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5- [2-propyloxy- 5- (l-methyl-2-pyrrolidinyleneamidosulfonyl) phenyl] - 1 -methyl - propyl-l,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure. |
| priorityDate | 2007-06-09^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 155 of 155.